Thomas Schmidt

Very happy to share that our manuscript is now online. Here we show the role of fibroblasts in colorectal cancer liver metastasis. Thank you to the whole team, especially to Ying @ShenYin17010393 and Xiaohong. Great collaboration with Alba @diz_lab authors.elsevier.com/a/1bCM85TA51TH…

📣 It's out! The PACT-21 CASSANDRA is on @TheLancet 🔵 Preoperative mFOLFIRINOX vs. PAXG for stage I–III PDAC 👑 PAXG prolonged median EFS (16 vs. 10 months) with similar adverse events 🧐 New standard of care !? #fig2" target="_blank" rel="nofollow noopener">thelancet.com/journals/lance…

@MarkarSheraz @NDSurgicalSci @ISDE_net @Augishealth @EAES_eu @young_esde Congrats Sheraz. Very well deserved.

Today one of the most important days in my professional career as promoted to full professor of UGI surgery @NDSurgicalSci. So proud of the national and international collaborations we are building in the UGI community. Too many people to thank, but genuinely so so grateful!

The role of length of oral resection margin and survival in esophageal cancer surgery after neoadjuvant therapy: A retrospective propensity score-matched study surgjournal.com/article/S0039-… Thank you @SurgeonSchmidt for your excellent OPEN ACCESS contribution to @SurgJournal

New impact factors are out! Selected surgical journals 👇 JAMA Surg 15.7 BJS 8.6 Ann Surg 7.5 JACS 3.8 BJS Open 3.5 EJSO 3.5 ASO 3.5 Surgery 3.2 DCR 3.2 Colorec Dis 2.9 HPB 2.7 Tech Coloproct 2.7 Hernia 2.6 Scand J Surg 2.5 Surg Endosc 2.4 WJS 2.3 J GI Surg 2.2 Langenbeck’s 2.1

Surgical and multimodal treatment of metastatic oesophageal cancer: retrospective cohort study ➡️doi.org/10.1093/bjsope… This retrospective single-centre cohort study included 235 patients with metastasized oesophageal cancer. A comparison was conducted of patient outcomes after resection alone, multimodal therapy including surgery, chemotherapy alone, any other therapy without surgery, or best supportive care as a treatment for metastasized oesophageal cancer. Resection or multimodal therapy including surgery resulted in the best overall survival in the total cohort and in subcohorts of patients with metachronous solid-organ metastases, with metastases in the liver, lung, or adrenal gland, or with a single metastasis. 👏👏👏Karl Knipper, Julian Lemties, Thaddaeus Krey, Su Ir Lyu, Naita M Wirsik, Lars M Schiffmann, Hans F Fuchs, Florian Gebauer, Wolfgang Schröder, Felix C Popp, Alexander Quaas, Hans A Schlößer, Christiane J Bruns, @SurgeonSchmidt #SoMe4Surgery #MedTwitter #SurgEd #Surgery @me4_so @for_surgery @for_surgeons @modern_surgeon @surggpt @BJSAcademy @BJSurgery @young_bjs @juliomayol @JJEarnshaw @OUPMedicine #some4UGI #uppergi #esophagealcancer @ISDE_net @Augishealth @roux_group @T4UGIS #ESDE @young_esde @lucasgoense @SMantziari @JessieAElliott @MarkarSheraz

Hyperthermic intraperitoneal chemotherapy in colorectal cancer ➡️doi.org/10.1093/bjsope… This is a large multicentric global study combining a number of large national peritoneal surface oncology databases from three continents (39 centres) for evaluating the use and choice of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasized colorectal cancer undergoing cytoreductive surgery. It is the largest study in the field of peritoneal surface oncology for colorectal cancer with crude survival analysis in over 2000 patients and propensity score matched survival analysis in over 1300 patients. This study found that oxaliplatin-based HIPEC resulted in superior overall and recurrence-free survival compared to mitomycin C-based HIPEC—a finding which persisted after propensity score matching. However, high-dose mitomycin C protocols resulted in improved survival, and a dose–response relationship between low-dose and high-dose HIPEC treatment regardless of protocol drug used was further discovered. 👏👏👏@OMaxFisher, Chris Brown, Jesus Esquivel, Stein G Larsen, Winston Liauw, Nayef A Alzahrani, David L Morris, Vahan Kepenekian, Isabelle Sourrouille, Frédéric Dumont, Jean-Jacques Tuech, Cécilia Ceribelli, Béranger Doussot, Olivia Sgarbura, Mohammed Alhosni, Francois Quenet, Olivier Glehen, @CashinPtr, Peritoneal Surface Oncology Group International (PSOGI), Nordic Peritoneal Oncology Group (NPOG), American Society for Peritoneal Surface Malignancy (ASPSM) and BIG-RENAPE Groups #SoMe4Surgery #MedTwitter #SurgEd #Surgery @me4_so @for_surgery @for_surgeons @modern_surgeon @surggpt @BJSAcademy @BJSurgery @young_bjs @juliomayol @JJEarnshaw @OUPMedicine #colorectalsurgery #colorectalcancer @FightCRC #StepUp4CRC #HIPEC

Can video assessment of surgical skills using OSATS (score 12-60) during #Robot #Pancreatoduodenectomy predict the risk of POPF? 153 PJ videos @DPCG_official OSATS <49 ➡️ 43.6% POPF OSATS ≥49 ➡️ 15.8% POPF journals.lww.com/annalsofsurger…

I strongly recommend applying here. The chances are very good. We on the EDS board particularly welcome applications from surgeons in training.

Our Computational Surgical oncology team is on track ✅ Jin-On Jung published that random survival forest is the optimal machine learning algorithm to predict survival in resectable gastroesophageal cancer ❗ rdcu.be/dfztz More to come 🔥…lnkd.in/ePFHx_TK

Our Computational Surgical oncology team is on track ✅ Jin-On Jung published that random survival forest is the optimal machine learning algorithm to predict survival in resectable gastroesophageal cancer ⏫ More to come 💡 @uniklinik_hd @UKKoeln rdcu.be/dfztz

Prediction of postoperative complications after esophagectomy 🟰 neuronal network ✅ Other prediction models did not perform equally for Clavian Dindo ≥ IIIa 🚫 Jin-On Jung in my team of Cologne Computational Surgical Oncology @UKKoeln @BJSurgery academic.oup.com/bjs/article-ab…

#bernierecommends 👀 Perioperative CTx with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: 10 years real-life experience from a surgical perspective rdcu.be/c5Qcr Leila Sisic et al. @HenrikNien @beatpetemueller @SurgeonSchmidt

@plitsah @Fischblog @BMauschen @Sander_Lab @RicardoLange4 @dgfn_ev @gunnar_heine @BuckerGunnar @oegnephro You should have this checked and most likely make an appointment with a nephrologist

@fischblog @BMauschen @Sander_Lab @RicardoLange4 @dgfn_ev @gunnar_heine @BuckerGunnar @oegnephro @SurgeonSchmidt HELP! Pls advice! Son, 24 yrs,183cm,76kg:RR 150/80 mmHG, Blood: Kreatinin 1,25mg/dl, EGFR 76,1 ml/min, CRP 10,5 mg/l, Leuko 12,6/nl. Urine: Albumin++, Erythrozyten++

Last touches on egumips.org 110 agreed statements (57 for lap and 53for robotic MIPS) .17 best video candidates . 8 endorsing societies &a great faculty. Looking forward to seeing you in Brescia @poliambulanza @EAHPBA @IHPBA @SAGES_Updates @e_mips @MarcBesselink 🎉👍

How gendered is the clothing offer for children? For our @SZ data analysis, we examined 20,000 shirts and shorts from @hmdeutschland, @Zalando and @aboutyou_com that they offer online for children under 10. The results show: Current children's fashion cements gender images. 🧵

@NawazUsmanDr @Manishbhandare4 @DrVAChaudhari @IHPBA @AHPBA My pleasure and honour 😎I know the feeling. I myself owe a lot to Markus Buchler and Helmut Friess @surgery_hps @JorgKleeff @doctor_felix @ProbstPascal @SurgeonSchmidt

Outcome #Pancreatic #Surgery during 1st 6 yrs of a nationwide 🇳🇱 audit? In-hospital mortality after #pancreatoduodenectomy improved ✅ 4.1%➡️2.4% related to FTR 13.4%➡️ 7.4% although ⬆️ high-risk pts. Impact biggest in high vol centers. Collaboration! journals.lww.com/annalsofsurger…

🧪 Postoperative Hyperamylasemia (POH) adds value to FRS in predicting POPF 🐳 😱 50% of POH eventually develop POPF 😵‍💫 POH limits FRS predictive accuracy!!! 👉 POPF risk assessment is a dynamic process including FRS, POH and drain amylase 👈 journals.lww.com/annalsofsurger…

#openaccess in @BJSurgery‘s August issue: Pancreatic surgery with or without drainage: propensity score-matched study academic.oup.com/bjs/article/10… @doctor_felix @KFKowalewski @HaneyCaelan @ProbstPascal @SurgeonSchmidt @markus_diener @beatpetemueller